NanoVibronix, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- NanoVibronix, Inc. is a medical device company specializing in the development and commercialization of non-invasive biological response-activating devices utilizing proprietary low-intensity acoustic ultrasound technology. Its core product portfolio includes UroShield and UroShield Ultra, ultrasound-based devices designed to prevent bacterial colonization and biofilm formation on urinary catheters, thereby reducing the risk of catheter-associated urinary tract infections (CAUTI) and enhancing antibiotic efficacy; PainShield, a patch-based therapeutic ultrasound technology available in single and dual patch configurations (PainShield MD and PainShield Plus) to treat pain, muscle spasms, and joint contractures; and WoundShield, a patch-based device intended to facilitate tissue regeneration and wound healing. These products offer home administration without medical professional assistance and are marketed primarily in the United States and Israel from the company's headquarters in Elmsford, New York. Founded in 2005, NanoVibronix targets the medical equipment industry with a focus on pain therapy, wound care, biofilm prevention, and urology segments. In 2025, NanoVibronix undertook a strategic refocus and rebranding effort following its acquisition of ENvue Medical Holdings, which brought in the ENvue feeding-tube placement system. This FDA-cleared electromagnetic navigation platform provides real-time visualization and guidance during enteral feeding tube placement, enhancing procedural safety and accuracy while reducing misplacement risks. The company has launched the ENvue Drive, an intelligent robotic platform designed to automate electromagnetic navigation for enteral and vascular access procedures at the bedside, targeting a significant $10+ billion market opportunity. NanoVibronix has secured agreements for commercial deployment of ENvue systems in U.S. hospitals starting in 2025, emphasizing their focus on integrated, technology-driven clinical solutions. Additionally, NanoVibronix executed a 1-for-10 reverse stock split and successfully completed equity financing rounds to support its expanded product pipeline, which now encompasses both therapeutic ultrasound devices and advanced electromagnetic navigation technologies. Overall, NanoVibronix operates primarily in the United States and Israel, leveraging its patented miniature transducer technology that transmits low-frequency, low-intensity ultrasound through flexible surfaces. The company serves healthcare providers, hospitals, and patients requiring non-invasive, drug-free therapeutic and procedural medical devices for pain management, infection control, wound healing, and accurate feeding tube placement. NanoVibronix’s recent strategic acquisitions and product innovations reflect a broader shift into electromagnetic navigation and robotic-assisted medical platforms, complementing its established desktop and patch-based ultrasound therapy portfolio to create a diversified medical technology company with expanding clinical applications and market reach.
ENvue Medical Strengthens Patent Portfolio with New USPTO Notice of Allowance for Feeding Tube Combining Electromagnetic Navigation with Direct Visualization Through an Integrated Internal Camera
ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research
ENvue Medical, Formerly NanoVibronix, UroShield® Kit Secures Reimbursement in the UK
NanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED'
Head to Head Review: Veracyte (NASDAQ:VCYT) vs. Nanovibronix (NASDAQ:NAOV)
NanoVibronix Issues Letter to Shareholders
NanoVibronix Launches “Oscar” Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities
NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical's Intellectual Property Portfolio
NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical’s Intellectual Property Portfolio
NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology
NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology
NanoVibronix Announces Reverse Stock Split
NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock
NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation
NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement
ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System
NanoVibronix Announces CEO Transition
NanoVibronix Responds to False Post